Stable Angina Management Market Snapshot (2023 to 2033)
The global Stable Angina Management Market is expected to garner a market value of US$ 11 Billion in 2023 and is expected to accumulate a market value of US$ 25.1 Billion by registering a CAGR of 8.6% in the forecast period 2023 to 2033. The market for Stable Angina Management registered a CAGR of 5.2% in the historical period 2018 to 2022.
Pharmaceutical products commonly used for the treatment of stable angina include antiplatelet agents, such as aspirin and clopidogrel, and nitroglycerin, which helps to relax and widen blood vessels. Beta-blockers, calcium channel blockers, and ACE inhibitors may also be prescribed to manage stable angina.
Medical devices used for the management of stable angina include stents, which are small mesh tubes that are inserted into narrowed or blocked arteries to improve blood flow, and coronary artery bypass surgery (CABG), which involves rerouting blood flow around a blocked or narrowed artery.
The stable angina management market is driven by factors such as the growing prevalence of cardiovascular diseases, increasing adoption of advanced medical technologies, and rising healthcare expenditure. However, the market may face challenges such as the availability of alternative treatment options, high cost of some treatments, and limited access to healthcare in certain regions.
Report Attribute
Details
Expected Market Value (2023)
US$ 11 Billion
Anticipated Forecast Value (2033)
US$ 25.1 Billion
Projected Growth Rate (2023 to 2033)
8.6% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Stable Angina Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider, Future Market Insights- the market for Stable Angina Management reflected a value of 5.2% during the historical period, 2018 to 2022. The stable angina management market is expected to grow in the coming years due to various factors such as the rising prevalence of cardiovascular diseases, increasing demand for effective treatment options, and the adoption of advanced medical technologies.
The increasing prevalence of cardiovascular diseases and the growing geriatric population are expected to be the major driving factors for the market's growth. Moreover, the increasing adoption of innovative technologies such as drug-eluting stents, bioresorbable stents, and optical coherence tomography (OCT) for the diagnosis and treatment of stable angina is expected to drive market growth. The increasing demand for minimally invasive procedures is also expected to drive the market's growth as they offer less discomfort, shorter recovery times, and lower healthcare costs compared to traditional open-heart surgeries.
Overall, the market for Stable Angina Management is expected to register a CAGR of 8.6% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Stable Angina Management Market?
Increasing Prevalence of Cardiovascular Diseases to Push Market Growth
The rising prevalence of cardiovascular diseases is expected to be one of the major drivers pushing the growth of the stable angina management market. Cardiovascular diseases (CVDs) are a group of disorders that affect the heart and blood vessels, and they are among the leading causes of death and disability worldwide. Stable angina is one of the most common forms of CVDs.
According to a report by the World Health Organization (WHO), CVDs are the leading cause of death globally, with an estimated 17.9 million deaths annually. The report also highlights that four out of five CVD deaths are due to heart attacks and strokes, which are often caused by a blockage that prevents blood flow to the heart or brain.
As the prevalence of CVDs continues to rise globally, the demand for effective treatment options for stable angina is also expected to increase. This is likely to drive the growth of the stable angina management market, as more patients seek medical interventions to manage their condition.
Moreover, the increasing incidence of risk factors for CVDs, such as high blood pressure, high cholesterol, obesity, and diabetes, is also contributing to the rise in CVDs. This is expected to further increase the demand for stable angina management products and services.
Overall, the rising prevalence of CVDs, along with increasing awareness and a growing demand for effective treatment options, is expected to push the growth of the stable angina management market in the coming years.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Stable Angina Management Market?
Expensive Cost of Treatment to restrict Market Growth
The high cost of treatment is a major challenge for the stable angina management market. The cost of diagnostic tests, medications, and procedures can be prohibitively expensive, especially for patients in developing countries. This can limit access to treatment options and hinder market growth.
The regulatory environment can also pose challenges to the stable angina management market. The approval process for new medical devices and treatments can be lengthy and expensive, and regulatory requirements can vary from country to country. Overall, while the stable angina management market has significant growth potential, it also faces several challenges that need to be addressed to ensure sustained growth and development.
Region-Wise Insights
How is the Stable Angina Management Market Turning Out in the South & East Asia Region?
Increasing awareness and diagnosis of the condition Shaping Landscape for Stable Angina Management in South & East Asia
One of the major drivers of the market growth in the region is the increasing prevalence of cardiovascular diseases, including stable angina. The rising incidence of risk factors such as obesity, high blood pressure, and diabetes, coupled with lifestyle changes, is contributing to the growing burden of cardiovascular diseases in the region.
Another factor contributing to the market growth is the increasing adoption of advanced medical technologies for the diagnosis and treatment of stable angina. The region has witnessed significant investments in the development of innovative medical devices and therapies, which are expected to drive market growth.
Moreover, the increasing healthcare expenditure by governments and private organizations in the region is expected to fuel the market's growth. Governments in the region are investing heavily in the development of healthcare infrastructure, which is expected to improve access to healthcare services for the population.
Overall, the stable angina management market in the South & East Asia region is expected to grow in the coming years, driven by the increasing prevalence of cardiovascular diseases and the adoption of advanced medical technologies. However, addressing the challenges and improving access to healthcare services and treatments will be critical for sustained market growth.
What are the Factors Boosting the Market for Stable Angina Management in North America?
Increasing Focus on Technological advancements Shaping Landscape for Stable Angina Management in North America
The market for Stable Angina Management in North America is expected to grow due to several factors. The North American region has a high prevalence of cardiovascular diseases, including stable angina. According to the American Heart Association, cardiovascular diseases are the leading cause of death in the United States, with approximately 18.6 million adults diagnosed with coronary heart disease. The high prevalence of cardiovascular diseases is expected to drive the demand for stable angina management products and services in the region.
Secondly, the North American region is at the forefront of technological advancements in the healthcare sector. The development of advanced medical devices and therapies, such as drug-eluting stents, implantable cardioverter-defibrillators, and transcatheter aortic valve replacement (TAVR), has improved the diagnosis and treatment of stable angina. These advancements are expected to drive market growth in the region.
North America has one of the highest healthcare expenditures in the world. According to the Centers for Medicare & Medicaid Services (CMS), national health expenditures in the United States reached $3.8 trillion in 2019, accounting for 17.7% of the country's GDP. The high healthcare expenditure is expected to drive market growth as it improves access to healthcare services and treatments for patients with stable angina.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By Distribution Channel, Which Segment is Likely to Account for a Significant Share?
Hospital pharmacies segment to hold a significant share and push market growth
Hospital pharmacies are the primary distribution channels for stable angina management products and services. They have access to a wide range of products, including prescription drugs, medical devices, and surgical instruments, and they are well-equipped to handle complex patient cases. In addition, hospital pharmacies have the advantage of being able to provide patients with a range of healthcare services, including consultation with healthcare professionals, medication counseling, and monitoring of medication adherence.
Moreover, the hospital pharmacies segment is expected to grow due to the increasing number of hospital admissions for cardiovascular diseases, including stable angina. Hospitals are the primary point of care for patients with cardiovascular diseases, and they play a critical role in managing the disease and preventing complications. As a result, hospital pharmacies are likely to account for a significant share of the stable angina management market.
Market Competition
Key players in the market include companies such as Competition Deep Dive, Abbott, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc. along with healthcare providers and technology companies among other global players.
In Early 2022, Health Canada granted approval for Corzyna as an additional therapy for patients suffering from stable angina who do not respond well to or cannot tolerate first-line therapies. Corzyna is considered a second-line therapy and is more expensive than the current treatment options for angina, with an annual cost of $2,555. This medication is recommended to be placed under Special Authorization for ClaimSecure groups subscribing to Managed Plans to ensure it is reserved for patients who have tried or are intolerant to more cost-effective options, while it will be fully covered for groups subscribing to Open Formularies.
Corzyna is a new medication that has been found to decrease the occurrence of angina attacks when used with first-line agents like beta-blockers and calcium channel blockers, as compared to the use of first-line therapies alone. In addition, for those who are intolerant to first-line therapy, Corzyna can be added to lower the dose of first-line therapy, thereby reducing the risk of undesirable side effects such as low blood pressure or heart rate.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 11 Billion
Market Value in 2033
US$ 25.1 Billion
Growth Rate
CAGR of 8.6% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
Distribution Channel
Drug Class
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
USA
Canada
Brazil
Mexico
Rest of Latin America
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Malaysia
Singapore
China
India
Thailand
Rest of South Asia
Gulf Cooperation Council
Japan
South Korea
Australia
New Zealand
GCC countries
South Africa
Israel
Rest of MEA
Key Companies Profiled
Competition Deep Dive, Abbott, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, ALLERGAN, Gilead Sciences, Inc., GlaxoSmithKline plc., Novartis AG, Pfizer Inc.
Customization
Available Upon Request
Key Segments Profiled in the Stable Angina Management Industry Survey
Drug Class:
Beta Blockers
Calcium Antagonists
Anti-coagulants
Antiplatelets
Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Frequently Asked Questions
At what rate did the Stable Angina Management Market flourish from 2018 to 2022?
From 2018 to 2022, Stable Angina Management Market grew at a CAGR of 5.2%.
What will be the growth rate of the global Stable Angina Management Market during the forecast period?
The global Stable Angina Management Market is expected to grow with a 8.6% CAGR during 2023 to 2033.
What will be the projected market size of the Stable Angina Management Market by 2033?
As of 2033, the Stable Angina Management Market is expected to reach US$ 25.1 Billion
Which segment of the Distribution Channel is expected to dominate the global Stable Angina Management Market during 2033?
According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
How is the North America Stable Angina Management Market projected to grow in 2033?
North America is expected to possess 40% market share for the Stable Angina Management Market.
How Big is the Market in 2023?
The market is valued at US$ 11.0 billion in 2023.
Who are the Key Market Players?
Abbott, AstraZeneca, and Bayer AG are the key market players.
How was the Historical Performance of the Market?
The market registered a CAGR of 5.2% from 2018 to 2022.
What Opportunities Await the Market Players?
Rising cases of cardiovascular diseases globally boost the market growth.
Which is the Key Segment by Distribution Channel?
The hospital pharmacies segment is likely to remain preferred through 2033.
Table of Content
1. Executive Summary | Stable Angina Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Beta Blockers
5.3.2. Calcium Antagonists
5.3.3. Anti-coagulants
5.3.4. Anti-Platelets
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Online pharmacies
6.3.2. Hospital pharmacies
6.3.3. Retail pharmacies
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Drug Class
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug Class
15.1.2.2. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug Class
15.2.2.2. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug Class
15.3.2.2. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug Class
15.4.2.2. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug Class
15.5.2.2. By Distribution Channel
15.6. United kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug Class
15.6.2.2. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug Class
15.7.2.2. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug Class
15.8.2.2. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug Class
15.9.2.2. By Distribution Channel
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug Class
15.10.2.2. By Distribution Channel
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug Class
15.11.2.2. By Distribution Channel
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug Class
15.12.2.2. By Distribution Channel
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug Class
15.13.2.2. By Distribution Channel
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug Class
15.14.2.2. By Distribution Channel
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug Class
15.15.2.2. By Distribution Channel
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug Class
15.16.2.2. By Distribution Channel
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug Class
15.17.2.2. By Distribution Channel
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug Class
15.18.2.2. By Distribution Channel
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug Class
15.19.2.2. By Distribution Channel
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug Class
15.20.2.2. By Distribution Channel
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Drug Class
15.21.2.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Abbott
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. AstraZeneca
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Bayer AG
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Bristol-Myers Squibb Company
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. F. Hoffmann-La Roche Ltd
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. ALLERGAN
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Gilead Sciences, Inc.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. GlaxoSmithKline plc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Novartis AG
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Pfizer Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 21: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 24: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 58: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 68: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 70: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 71: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 73: South Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 74: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 76: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 83: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 88: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 91: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 92: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 98: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 100: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 101: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 103: Oceania Market Attractiveness by Drug Class, 2023 to 2033
Figure 104: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 106: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 107: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 113: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 114: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 115: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 116: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 117: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 118: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 119: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
